DCM
ALPN

DAFNA Capital Management’s Alpine Immune Sciences Inc ALPN Stock Holding History

DAFNA Capital Management’s Portfolio ALPN Stock Details ALPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-111,501
Closed -$1.19M – 90
2021
Q3 		$1.19M Sell
111,501
-1,801
-2% -$16.6K 0.32% 67
2021
Q2 		$1.02M Hold
113,302
– – 0.21% 71
2021
Q1 		$1.2M Buy
113,302
+100
+0.1% +$1.25K 0.28% 69
2020
Q4 		$1.43M Sell
113,202
-35,058
-24% -$344K 0.42% 49
2020
Q3 		$1.3M Buy
+148,260
New +$1.36M 0.42% 48
2016
Q4 		– Sell
-3,750
Closed -$122K – 74
2016
Q3 		$122K Hold
3,750
– – 0.09% 69
2016
Q2 		$69K Hold
3,750
– – 0.05% 86
2016
Q1 		$63K Hold
3,750
– – 0.05% 89
2015
Q4 		$116K Hold
3,750
– – 0.1% 72
2015
Q3 		$195K Hold
3,750
– – 0.19% 72
2015
Q2 		$227K Buy
+3,750
New +$223K 0.19% 63

Other funds holding ALPN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DAFNA Capital Management's ALPN Position: Q4 2021 in Review

DAFNA Capital Management sold out of Alpine Immune Sciences Inc (ALPN) in Q4 2021, closing a stake of 111,501 shares — an estimated $1.19M sold.

DAFNA Capital Management first reported a position in ALPN in Q2 2015 and held it in 11 quarters. The position peaked at $1.43M in Q4 2020. 53 funds tracked by Wall St. Rank hold ALPN as of Q4 2021.

  • DAFNA Capital Management reported no remaining Alpine Immune Sciences Inc position as of Q4 2021 after selling out during the quarter.
  • DAFNA Capital Management sold 111,501 Alpine Immune Sciences Inc shares in Q4 2021, an estimated $1.19M.
  • DAFNA Capital Management first reported a position in Alpine Immune Sciences Inc in Q2 2015 and held it in 11 quarters.
  • DAFNA Capital Management's Alpine Immune Sciences Inc position peaked at $1.43M in Q4 2020.
  • 53 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q4 2021.

Based on DAFNA Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.